Pyoderma gangrenosum

Phillip J. Eichhorn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pyoderma gangrenosum (PG) is a chronic ulcerative skin disease with striking clinical features that may rarely involve internal organs, particularly the lung, liver, and spleen. Approximately 50% of PG patients have associated inflammatory, immune dysfunction, or neoplastic diseases. The various topical, systemic, and surgical treatment options for PG are reviewed here. Systemic corticosteroids plus immunosuppressive therapy are often required to successfully manage severe cases of PG. Practical treatment strategies are discussed along with their proper monitoring and potential adverse effects. Current treatment methods are empiric, and the optimum treatment regimen for this disorder requires future controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)102-110
Number of pages9
JournalDermatologic Therapy
Volume14
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Pyoderma Gangrenosum
Therapeutics
Controlled Clinical Trials
Immunosuppressive Agents
Skin Diseases
Adrenal Cortex Hormones
Spleen
Lung
Liver

Keywords

  • Cyclophosphamide
  • Cyclosporine A
  • Mycophenolate mofetil
  • Pyoderma gangrenosum
  • Systemic corticosteroids

ASJC Scopus subject areas

  • Dermatology

Cite this

Pyoderma gangrenosum. / Eichhorn, Phillip J.

In: Dermatologic Therapy, Vol. 14, No. 2, 2001, p. 102-110.

Research output: Contribution to journalArticle

Eichhorn, Phillip J. / Pyoderma gangrenosum. In: Dermatologic Therapy. 2001 ; Vol. 14, No. 2. pp. 102-110.
@article{0452dc7b50fe469ea727c5c53cbbd955,
title = "Pyoderma gangrenosum",
abstract = "Pyoderma gangrenosum (PG) is a chronic ulcerative skin disease with striking clinical features that may rarely involve internal organs, particularly the lung, liver, and spleen. Approximately 50{\%} of PG patients have associated inflammatory, immune dysfunction, or neoplastic diseases. The various topical, systemic, and surgical treatment options for PG are reviewed here. Systemic corticosteroids plus immunosuppressive therapy are often required to successfully manage severe cases of PG. Practical treatment strategies are discussed along with their proper monitoring and potential adverse effects. Current treatment methods are empiric, and the optimum treatment regimen for this disorder requires future controlled clinical trials.",
keywords = "Cyclophosphamide, Cyclosporine A, Mycophenolate mofetil, Pyoderma gangrenosum, Systemic corticosteroids",
author = "Eichhorn, {Phillip J.}",
year = "2001",
doi = "10.1046/j.1529-8019.2001.014002102.x",
language = "English (US)",
volume = "14",
pages = "102--110",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pyoderma gangrenosum

AU - Eichhorn, Phillip J.

PY - 2001

Y1 - 2001

N2 - Pyoderma gangrenosum (PG) is a chronic ulcerative skin disease with striking clinical features that may rarely involve internal organs, particularly the lung, liver, and spleen. Approximately 50% of PG patients have associated inflammatory, immune dysfunction, or neoplastic diseases. The various topical, systemic, and surgical treatment options for PG are reviewed here. Systemic corticosteroids plus immunosuppressive therapy are often required to successfully manage severe cases of PG. Practical treatment strategies are discussed along with their proper monitoring and potential adverse effects. Current treatment methods are empiric, and the optimum treatment regimen for this disorder requires future controlled clinical trials.

AB - Pyoderma gangrenosum (PG) is a chronic ulcerative skin disease with striking clinical features that may rarely involve internal organs, particularly the lung, liver, and spleen. Approximately 50% of PG patients have associated inflammatory, immune dysfunction, or neoplastic diseases. The various topical, systemic, and surgical treatment options for PG are reviewed here. Systemic corticosteroids plus immunosuppressive therapy are often required to successfully manage severe cases of PG. Practical treatment strategies are discussed along with their proper monitoring and potential adverse effects. Current treatment methods are empiric, and the optimum treatment regimen for this disorder requires future controlled clinical trials.

KW - Cyclophosphamide

KW - Cyclosporine A

KW - Mycophenolate mofetil

KW - Pyoderma gangrenosum

KW - Systemic corticosteroids

UR - http://www.scopus.com/inward/record.url?scp=0035005367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035005367&partnerID=8YFLogxK

U2 - 10.1046/j.1529-8019.2001.014002102.x

DO - 10.1046/j.1529-8019.2001.014002102.x

M3 - Article

AN - SCOPUS:0035005367

VL - 14

SP - 102

EP - 110

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 2

ER -